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Abstract
1. Properdin assay which is comparatively sensitive and reproducible has been described. The
assay may be called a modified method of properdin assay by HUNTER·HILL and McNALL. 2.
The properdin assay of serum is possible by using a very small amount of test serum (0.1 ml at
the least). The necessary amount of zymosan is very little, the procedure of properdin assay is
comparatively simple and it can safely be used clinically. 3. Serum properdin of guinea pig, rat,
rabbit and mouse can easily be measured by means of Rp and Ra made from guinea-pig sera. 4.
In the properdin assay of human serum, human Rp serum IS preferable to guinea-pig Rp serum. 5.
Human Rp serum is always prepared easily from pooled sera of advanced cancer bearing patients.
6. Insulin has not such ability of making Rp and R3 as can replace zymosan. 7. Properdin assay
is possible by means of goat’s hemolytic system as well as sheep’s hemolytic system.
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The properdin system1•2•4 discovered by PILLEMER (1954) is one of the
serum mechanisms which appears to be involved in natural resistance. This
system is composed of properdin, complement and magnesium. Properdin differs
from the immune antibody in many respects: in that properdin is not a r-globulinbut a p-globulin:\ in that it lacks serological specificity, and in that serum
factors are necessary for properdin to combine with zymosan and the complex
inactivates selectively the third component of complement, while the usual
antigen-antibody requires no factors and inactivates four components of comple-
ment except third component. Various methods for the assay of properdin based
on inactivation of the third component of complement (C'a) are known. The
original method with zymosan by PILLEMER et al. loot has been modified by
ISLIKER5•tl, KENT et ae, FRITZSCHE et al/", ZANUSSI~ and DRESSLERlO• That
with inulin instead of zysmosan was tried by McNALLll , HUNTER and HILL12,
BIANCHI et al.J:", and SCHEIFFARTH et al.14 In practice, the attempt with these
methods presents many difficulties inherent in various reagents and cofactors
that take part in these reactions. The procedures proposed by PILLEMER and its
modified forms except that of McNALL, HUNTER and HILL are too complex tobe applicable for the clinical study. Actually in employing HUNTER and HILL's
method, a considerable modification of this method and for the preparation of
reagents is needed to obtain reproducible and constant results.
Therefore, the present study was undertaken for the purpose of finding
out a hetter method for the properdin assay.
MATERIALS AND METHODS
1) Serum: Blood of guinea pig, mouse and rat is collected by cardiac
puncture, blood of rabbit from the peripheral vein of ear, human blood from
the elbow vein. Blood is allowed to clot at room temperature for two hours.
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The serum is separated by centrifugation for 15 minutes at 4000 r. p. m. and
recentrifuged to remove residual red cells. These clear, unhemolyzed sera are
then stored at 1°C, if used within a 12-hour period, or stored at -30°C in the
sealed tubes for later use. These sera are thawed immediately before the use.
During manipulation, care should be taken to avoid bacterial contamination.
2) Hemolytic system:
a) Suspension of goat erythrocytes: The goat blood drawn from jugular
vein and defibrinated is collected in an equal volume of Alsever's solutionIS and
stored at 4°C. The blood is kept 4 days before the use and discarded after 10
days. A portion of the blood is removed asepti~ally each day, and washed 3
times with 10 volumes of 0.85 per cent saline solution. The final supernatant
should be entirely colorless. The suspension of cells is prepared with isotonic
saline solution. The desired degree of dilution should be such that 1.0 ml of the
suspension after hemolysis with 4.0 ml of distilled water indicates a reading in
20 on the Beckmann's spectrophotometer at 540 mp.. using a water blank.
Ordinarily this dilution is about 4 per cent suspension.
b) Hemolysin: Hemolysin is obtained by immunizing rabbits with washed
goat red cells, stored at 1°C and its titer is determined at monthly intervals.
Under such a condition, hemolysin can be used over one year. An equal volume
of isotonic saline solution, containing 2 units of hemolysin, is added into the
standardized red cells. The sensitized cells kept in ice water are used only within
a 12-hour period after the preparation.
3) The titration of complement (C'): The procedure of this titration is as
follows: the serum under test is diluted with saline solution, according to the
two-fold dilution method 1.0 ml portion of the standardized, sensitized goat red
cells is added to Wassermann tubes containing 0.5 ml of diluted serum from
1 : 1 to 1 : 128. A set of tubes is incubated at 37°C for 30 minutes with occa-
sional shaking. One unit of C' is the minimum amount of serum necessary to
produce complete hemolysis of 1.0 ml of sensitized goat cells.
4) Preparation of reagents for the titration of individual components of
complement.
a) Heat inactivated serum: 1.0 ml of fresh guinea-pig serum in test tube
is heated at 56°C for 20 minutes, and then 9.0 ml of saline is supplemented to
a dilution of 1 : 10 before the use.
b) Reagent for C'I , (RI) and C'2 (Rz): CO2 dilution method is used
following LIEFMANNlli . 17 • C02 evolving from Kipp's apparatus is conducted
into fresh guinea-pig serum 1.0 ml diluted with 8.5 ml of distilled water. After
10 minutes, the precipitate or globulin fraction is centrifuged off for 30 minutes
at 4000 r. p. m., separated from the supernatant or albumin fraction. The su-
pernatant is diluted with 1.5 mlof 17 percent saline to 1 : 10 isotonic solution.
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On the other hand, the precipitate washed with distilled water is immersed in
9.5 ml of distilled water, and brought to 1 : 10 diluted isotonic solution with
addition of 17 per cent saline. The supernatant is deficient in C'l (midpiece),
and the precipitate in C'2 (endpiece). Rl is prepared by combination of 0.5 ml
of the supernatant with 0.2 ml of 1 : 10 dilution of heated serum which supplies
C'g and C'4. R2 can be prepared by adding 0.2 ml of 1 : 10 dilute, heated
serum to 0.5 ml of the precipitate made to isotonic solution.
c) Reagent for C'g, (R3): will be described later. .
d) Regent for C'4, (R4): 0.5 ml of 0.1 N NH40H is added to 1.0 mlof
fresh guinea~pig serum. The mixture is incubated for 75 minutes with occasi~
nalagitation, and neutralized with 0.5 ml of 0.1 N HCl, and then made to
isotonic dilution of 1 : 10 with 7.0 ml of isotonic saline after adding 1.0 ml of
1.7 per cent saline.
5) Titration of components of complement: The titration of four compon-
ents of complement relies on HEGEDUS and GRElNER's assumptionlll. The titers
of individual components are estimated by tw~fold dilution method as in the
previously mentioned complement titration except that reagents for the compon~
ents to be assayed are added to all the test tubes. Ordinarily 0.7 ml each of Rl
and R2 is added for the titration of C'l and C'2, and 0.5 ml each of R3 and
R4 with 0.2 ml of saline is used for the titration of C'g and C'4.
OBSERVATIONS AND RESULTS
1. Barbital buffer: The composition of pH 7.4 concentrated buffer~ is ase-ptically stored at 1°C. The commonly-used diluted buffer is prepared from
stock daily.
2. Zymosan: Zymosan was extracted three times from fresh yeast follow-ing PILLEMER's method~·l9. The zymosan obtained at the first treatment is
inactive Type E, the second and the third ones are both Type B which does not
make a suitable R3, but a useful Rp. However, these zymosan have lower
titers than one made in the Fleishmann Laboratories.
Zymosan used in the properdin assay:
1. Zymosan Type B.
2. Zymosan Type A. (Lot No. 7B 152, the Fleishmann Laboratories,
Stamford, Connecticut, U. S. A.)
Before the use, zymosan is suspended in 100 volumes of saline solution,
kept in a boiling water bath one hour, and then centrifuged for 30 minutes at
4000 r. p. m. The supernatant is discarded and the sediment is suspended uni-
'formly in the barbital buffer as to contain 40 mg per ·ml.
This suspension is kept at 1°C, avoiding contamination.
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3. Reagent for C'g, (Rg): Zymosan is previously tested for the minimal
amount required to complete inactivation of C'g in 1.0 ml of fresh guinea-pig
serum at 37°C for 75 minutes. Thus, Rg is prepared with fresh serum collected
from 5 or more guinea pigs by adding 4 mg of zymosan for each ml.of serum.
The mixture is incubated at 37°C for 75 minutes stirring every 15 minutes.
After this, it is centrifuged at 4000 r. p. m. for 30 minutes at 1°C. The clear
supernatant is divided into small amounts, frozen-dried and maintained in the
sealed tubes at 1°C. Before the use, barbital buffer is added to the frozen-dried
Rg to original volume.
The standardization of Rg:
(1) 0.2 ml of Rg should not be hemolytic for 2 ml of sensitized goat blood
cells.
(2) Rg should indicate the complement titer of 50 per cent of untreated
original serum, when added to other reagent (usually, heat inactivated
serum at 56°C for 30minutes).
(3) Rg should not be anticomplementary.
4. Properdin lacking serum containing all components of complement,
(Rp): Rp is prepared as follows, taking PILLEMER's and McNALL's procedure as
a reference: to each ml of sera is added a suitable amount of zymosan (1-2mg
at Fleishmann's zymosan, 4-6mg at one prepared by the author). The mixture
is maintained at 17°C for one hour, shaking every 15 minutes and then centri-
fuged at 4000 r. p. m. for 20 minutes. The same amount of zymosan is added
to the supernatant and the treatment as above is again repeated. The third in-
cubation was at 37°C for 20 minutes. After centrifugation at 4000 r. p. m. for
20 minutes, the supernatant divided in small vials is frozen-dried and kept at
-30°C.
The standardization of Rp:
(1) Rp should have a C' titer of at least 75 per cent of the original serum.
(2) When zymosan is added to original Rp and incubated at 37°C for one
hour, C'g titer should not be depressed to less than 75 per cent of the
original Rp.
(3) Rp should not be anticomplementary.
Rp prepared from pooled fresh guinea-pig sera is suitable to measure the
titers of properdin of guinea pig, rabbit, rat, and mouse sera, but not always
satisfactory for that of human sera. Rp for properdin assay of human sera is
obtained as follows: after sera of a number of untreated patients with advanced
cancer are collected, and stored at - 30°C, these titers of properdin and com-
plements are measured separately, and then sera having low levels of properdin,
high titers of complement and non-anticomplementary actions are selected as the
source of human Rp. Useful human Rp is obtained always by such procedures,
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but it is more difficult to remove properdin from human sera with zymosan.
Before the use, the Rp dissolved to the original volume is diluted with buffer to
the dilution factor showing the reading between 30 and 60 per cent transmit-
tance. Oridinarily, Ra is added to Rp in an equal volume.
5. Properdin assay.
This assay relies on the modified zymosan assay of PILLEMER et al. J•4 When
serum for test is incubated with zymosan and a suitable amount of Rp at 37°C,
zymosan combines with properdin of serum under test and this PZ complex
quantitatively removes C'a from this system, mainly from Rp.
The titer of the rest of C'a using the hemolytic system is spectrophoto-
metrically measured, plotted on the semilogarithmic paper, and then the pro-
perdin level is estimated, as shown previously by HUNTER and HILL12•
A. Preliminary examination.
When the interaction between properdin, zymosan, and C'a at 37°C is
performed, the reaction is greatly affected by the amount of zymosan, the time
of incubation, and the serum dilution factor.
a. The effect of zymosan concentration on the reaction between zymosan
properdin ~md C'a (Table 1).
Table 1. Milliliters of Reagent in Tube.
Reagent I A I B I 1 I 2 I a I 4 I 5 I 6 I 7 I 8 I
Rp+Ra* 0.3 o.a 0.3 0.3 0.3 0.3 I 0.3 0.3 o.a 0.3
--
Serumt 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.21 : 15 dil.
Zymosan 4mg 0.5mg 1.0mg 1.5mg 2.0mg 3.0mg 4.0mg 8.0mg40mg/ml
--
Buffer 0.4 0.3 0.187 0.175 0.16 0.15 0.125 0.1 0.2
* The mixed reagent is added in such a quantity that 30 to 60 per cent transmittance may
be observed and each tube is brought to 0.7 ml with addition of buffer.
t The pooled fresh rabbit serum.
1. Each test tube is incubated at 37°C for one hour with shaking every 10
minutes.
2. Centrifuged for 15 minutes at 4000 r. p. m., after adding of 2.3 ml of
saline.
3. 2.0 ml of sensitized goat red cells is added to each tube, and incubated
at 37°C for 30 minutes.
4. Centrifuged immediately at 3000 r. p. m. for 10 minutes at room tem-
perature.
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5. The transmittance of each supematant is read at 540 m,l. using Beck-
mann's spectrophotometer.
Result.s
A I B I l!-;---I---;-r-;-T-S-1 6 i -7T--8
I 41% I 43 I 46 I 56 I 58 I 58 I 53 I 60 I 64 I 34
The transmittance of supematants is constant in 1-4 mg of zymosan.
Hence, as illustrated in Table 1, 2mg of zymosan to each tube is considered as
a suitable amount.
b. The effect of the time of incubation on the reaction of zymosan (2mg)
with properdin and C/3 (Table 2).
Table 2. Milliliters of Reagent in Tube.
Reagent I A I B I 1 I 2 I 3 I 4 I 5 I 6 I 7 I 8
Rp+R:3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
------------
Serum 1 : 15 dil. 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
-----
------------------
Zymosan 10 mg/ml 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
--------
Buffer 0.4 0.2
--
--------
----
Incubation time 60 60 15 30 45 60 75 90
I
120 60(minutes)
Each tube is withdrawn after each incubation, brought to 3.0 ml with
2.3 ml of saline, and centrifuged. Each tube is treated in the same way
as described above and the transmittance of each supematant is read at
540 mll..
Results
A I B
42%1 43
1
38
2
46
3
52
4
58
5
57
6
60
7
66
8
33
The transmittance of supematants is constant in 45-90 minutes of in-
cubation. Hence, 60 minutes is considered as a suitable time of incubation.
c. The effect of serum dilution factor on the reaction of zymosan (2 mg)
with properdin and C/3 (Table 3).
Each tube is incubated at 37°C for 1 hr. and brought to 3.0 ml with
addition of buffer, and then treated in the same way as previously
described.
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Table 3. Milliliters of Reagent in Tube.
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Reagent I A I B 1 1 I 2 \ 3 I 4 I 5 I 6 I 7 I 8 I 9~P_+R~ I,~ 0.3 1_ ~I--~'-~-!-~:~J--~--~I~ 0.3 0.3 0.3
Serum 1 : 15 dil. I 0.2' 0.2 I 0.2 0.2 0.21 0.2 0.2 0.2 0.2
Zymosan20mg/ml 0.1~uu~~I~ 0.1 0.11
1 1_--
Buffer 0.4 0.3 0.1 0.3 0.5 1.0 1.4 2.0 2.4 0.2
----
--
--
--------Total 0.7 0.7 0.6 0.7 0.9 1.1 1.6 2.0 2.6 3.0 0.7
Results
A I ,B 1 2 3 4 5 \ 6 I 7 8 I 9
39%1 42 62 59 56 51 38 1 34 .5 1 34 38 \32.5
The transmittance of supernatants is constant with addition of 0-0.5
ml of buffer. Hence, the total volume of 0.7 ml is considered as a sui-
table amount in each test tube.
From the results of a. b. c., the protocol for properdin assay is esta-
blished as illustrated in Table 4.
Table 4. Milliliters of Reagent in Tube.
Reagent I A I B I 1 I 2 I 3 \ 4 \ 5 I 6 I c I
Rp+R3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
Serum 1: 15 dil. 0.1 0.2 0.3 0.1 0.2 0.3 0.4
Zymosan 20 mg/ml 0.1 0.1 0.1 0.1
-----Buffer 0.4 0.3 0.3 0.2 0.1 0.2 0.1 0.3
B. Properdin assay.
All glasswares are cleansed with dichromate-sulfuric acid, washed with dis-'
tilled water, and then dried at 120°C. Samples of sera are collected on the day
of the test, or frozen at - 30°C. All of the dilutions and mixtures are made
immediately before incubation and maintained in ice".bath.
The procedures for properdin assay are as follows (Table 4) : -
1. Wassermann test tubes containing the total volume of 0.7 ml mixture each
are incubated at 37°C for one hr. with shaking every 15 minutes.
2. Centrifuged for 15 minutes at 4000 r. p. m. to remove properdin-zymosan-
C/g complex from the mixture, and immediately 2.3 ml of saline warmed
at 37°C is added to each tube.
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3. Each 2.0 ml of sensitized goat cells is gently added taking care not to dis-
turb the sediment.
4. Incubated exactly for 30 minutes at 37°C.
5. Centrifuged immediately at 3000 r. p. m. for 10 minutes.
6. The hemoglobin concentration in the supernatant is read 540 m!l. using the
water blank for the 100 setting.
7. The transmittances thus obtained are plotted on the semilogarithmic' paper
as Fig. 1.
Fig. 1.
"3
~
./~
~
B~
fI
-----
I" ____
'b
.... ~
The differences between readings from tubes 1, 2, 3 and from tubes 4, 5, 6
represent the decrease in C'3 concentration. This decrease is equivalent to the
properdin level of test serum. The straight line is drawn through points A, 1,2
and 3, another line through points B, 4, 5 and 6. If the reagents (Rp+R3)
lack completely in properdin, points A and B are superimposed. On the other
hand, when sera containing one unit of properdin standardized by PILLEMER's
method are again treated as above for the measurement of properdin level in
this manner, one unit of properdin is reduced to a constant distance on semiloga-
rithmic paper.
Consequently, units of serum properdin for test are simply estimated from
both the number of centimeters between points 2 and 5 and dilution factors of
these sera. The properdin titers of various animals are nearly similar to those
shown by PILLEMER1,4.
When normal sera are typically treated, eight points constitute a regular
curve similar to an isosceles triangle as shown in Fig. 1.
HUNTER and HILL12 previously reported considerable informations on the
interpretation of abnormal curves that are occasionally observed.
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Pooled guinea-pig sera are routinely used as the source for Rp and R3 rea-
gent~, especially for the latter, because guinea-pig sera have the lowest pro-
perdin levels1•4 of any experimental animals, high complement and generally C'3
as the limiting component2J • Guinea-pig Rp sera are unsuitable to measure the
titers;'of properdin in human sera. Human Rp sera are more useful for human
properdin titrations. This fact may be related to the species incompatibilities.
Human sera have much higher properdin titer and lower complement than those
of guinea-pig sera, and limiting component is usually not C'3, but C'2. It is,
therefore, d~fficult to obtain human sera to make satisfactory Rp reagent.
According to PILLEMER, et al.4, the useful human Rp can only be prepared
from about 20 per cent of the human sera. In practice, it is difficult to look for
a donor with such a convenient blood, so sera of untreated patients with ad-
vanced cancer and without other disease are used as the source of human Rp.
The advantage of using these sera lies in the fact that most of the cancer bear-
ing human sel;"a lack or contain little properdin, and have comparatively high
titers of complementw•
In the components of complement of Rp C'3 is the limiting component, and
to assure this Rg is added to Rp. In guinea-pig and rat sera C'3 is generally
limiting component, so in the properdin assay of these sera R3 need not be
added to Rp. In human and rabbit sera the limiting component is generally C'2
and mouse sera lack or contain least amount of C'2 or C'4 22•ZJ .2'i, in the properdin
assay of these sera it is absolutely necessary to add R3 to Rp. Serum properdin
assay is taken the place of the measurement of the alterations in C'3 which is
contained in Rp test sera by means of goat's hemolytic system. Therefore, the
dilution factor of test sera must be adjusted in such way that the complement
titer of Rp + R3 + test sera (diluted 0.3 ml) may be lower than 2096 transmit-
tance and more than gO per cent. Ordinarily, properdin assay is possible in human,
rabbit and mouse sera by 15 X dilution and in rat sera by 30 x dilution.
The reason why every te~t tube is made to contain a small total amount
of 0.7 ml in the first step of incubation is as follows:
1. It is because the measurement of serum properdin is attempted by using very
small amount of test sera (0.1-0.2 ml). As is clear in the preliminary ex-
amination, dilution factor of test sera has a great effect on the reaction
among zymosan, properdin and C'8, and this fact is previously found by
LEON?4.
If the test serum is too dilute, the reaction stops and the properdin assay
becomes impossible. Therefore, it is desirable that dilution of the test sera
be as low as possible and total amount be limited to 0.7 ml.
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2. To make total amount kept small is for the purpose of saving zymosan.
3. Small amount of zymosan is used, therefore other components except C'a
are in little danger of being inactivated.
Since McNall's reported that inulin combines with properdin, inactivates C'a
in a manner similar to zymosan, can be used in a higher concentration than
zymosan and does not inactivate other components in high concentration,
inulin has been used as the C'a inactivating polysaccharide in preference to
zymosan lJ ,12,1:1,14.
Lots of inulin used in our laboratory are from Merk, Fisher, and Wako
Chemical Company (Japan). Each of them has no C'a inactivating power enough
to replace zymosan. Inulin varies with the lots in C'a inactivating ability, as
shown in zymosan.
In comparison with a routine method-PILLEMER's method1.4, the present pro-
perdin assay is easy to manipulate and the results are more constant and repro-
ducible. The quantity of C'a of the test sera is not taken into consideration in
the routine method. The relationship between bactericidal activity and pro·
perdin concentration in Rp suggests that a bactericidal assay for properdin25
should be possible, but Rp reagent used for this assay is very difficult to prepare.
The test organisms have to be sensitive only to the properdin system in the test
serum but not to Rp. Antibody or bactericidal activities of serum other than the
properdin system ma'y interfere with the system. Consequently, the bactericidal
assay is not suitable method.
The method applying the hemolysis of erythrocytes treated with tannic
acid26 is suitable for assay of purified properdin, but not for the quantitative
measurement of properdin in serum, because these red cells are hemolysed by
heterolysins independent of the properdin system.
The properdin assay using the Rp reagent prepared from the same serum
for test is very laborious to perform and takes longer time111•
CONCLUSIONS
1. Properdin assay which is comparatively sensitive and reproducible has been
described. The assay may be called a modified method of properdin assay
by HUNTER·HILL and McNALL.
2. The properdin assay of serum is possible by using a very small amount of
test serum (0.1 ml at the least). The necessary amount of zymosan is very
little, the procedure of properdin assay is comparatively simple and it can
safely be used clinically.
3. Serum properdin of guinea pig, rat, rabbit and mouse can easily be measured
by means of Rp and Ra made from guinea-pig sera.
10
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'4. In the properdin assay of human serum, human Rp serum IS preferable to
guinea-pig Rp serum.
5. Human Rp serum is always prepared easily from pooled sera of advanced
cancer bearing patients.
6. Insulin has not such ability of making Rp and R3 as can replace zymosan.
7. Properdin assay is possible by means of goat's hemolytic system as well as
sheep's hemolytic system.
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